Health Care [ 7/12 ] | Biotechnology [ 39/74 ]
NASDAQ | Common Stock
Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States.
Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes used for the treatment of hemolytic anemias in adults with PK deficiency.
The company's PYRUKYND product also used for the treatment of sickle cell disease that is in phase 3 clinical trial; for the treatment of PK deficiency in pediatric patients; and for the treatment of adult patients with non-transfusion dependent and transfusion-dependent alpha- or beta-thalassemia.
In addition, it develops tebapivat, a PK activator for the treatment of lower-risk myelodysplastic syndrome and hemolytic anemias; AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria (PKU); and AG-236, an siRNA in-licensed from Alnylam, targeting the transmembrane serine protease 6 (TMPRSS6) gene for the treatment of polycythemia vera.
Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Feb 13, 25 | -1.74 Decreased by -1.16% | -1.63 Decreased by -6.75% |
| Oct 31, 24 | -2.42 Decreased by -47.56% | 1.11 Decreased by -318.02% |
| Aug 1, 24 | -1.69 Decreased by -11.92% | -1.60 Decreased by -5.62% |
| May 2, 24 | -1.45 Increased by +1.36% | -1.65 Increased by +12.12% |
| Feb 15, 24 | -1.72 Decreased by -356.72% | -1.65 Decreased by -4.24% |
| Nov 2, 23 | -1.64 Decreased by -10.07% | -1.70 Increased by +3.53% |
| Aug 3, 23 | -1.51 Increased by +10.12% | -1.56 Increased by +3.21% |
| May 4, 23 | -1.47 Increased by +15.52% | -1.70 Increased by +13.53% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 24 | 8.96 M Increased by +21.15% | 947.91 M Increased by +1.14 K% | Increased by +10.57 K% Increased by +956.75% |
| Jun 30, 24 | 8.62 M Increased by +28.35% | -96.12 M Decreased by -14.69% | Decreased by -1.12 K% Increased by +10.64% |
| Mar 31, 24 | 8.19 M Increased by +46.00% | -81.55 M Decreased by -14.18% | Decreased by -995.84% Increased by +21.79% |
| Dec 31, 23 | 7.10 M Increased by +64.80% | -95.94 M Decreased by -155.71% | Decreased by -1.35 K% Decreased by -133.80% |
| Sep 30, 23 | 7.40 M Increased by +110.44% | -91.32 M Decreased by -26.13% | Decreased by -1.23 K% Increased by +40.06% |
| Jun 30, 23 | 6.71 M Increased by +20.24% | -83.81 M Increased by +2.52% | Decreased by -1.25 K% Increased by +18.93% |
| Mar 31, 23 | 5.61 M Increased by +574.16% | -71.42 M Increased by +19.21% | Decreased by -1.27 K% Increased by +88.02% |
| Dec 31, 22 | 4.31 M Increased by +10.41 M% | 172.22 M Increased by +282.00% | Increased by +4.00 K% Increased by +100.00% |